SGLT2 Diary

SGLT2 Diary is a daily tracking app for people taking SGLT2 inhibitors — including canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, bexagliflozin, and sotagliflozin (Invokana, Farxiga, Jardiance, Steglatro, Brenzavvy, Inpefa). Log your weight, monitor common side effects, and spot patterns over time — all in seconds, all on your device. TRACK SYMPTOMS IN ONE TAP Record daily weight and SGLT2-related symptoms — fatigue, low blood pressure, light-headedness, genital itching, painful urination, and fever — with a single tap. No forms, no friction. 28-DAY CALENDAR HEAT MAP A color-coded calendar view shows how your weight and symptoms shift week by week. Your SGLT2 start date is highlighted automatically, so you can see exactly how your body has responded since day one. APPLE HEALTH INTEGRATION Sync body weight directly from HealthKit and eliminate duplicate data entry. Your Health app data flows into SGLT2 Diary automatically. YOUR DATA STAYS ON YOUR DEVICE No account required. No cloud upload. Everything is stored locally on your iPhone or iPad. CUSTOM ALERTS Set alert sounds, vibration, or both to confirm each log entry — useful for discreet reminders during the day. FREE TO USE SGLT2 Diary is free and supported by a single unobtrusive banner ad. ABOUT SGLT2 INHIBITORS Sodium-glucose cotransporter-2 inhibitors are oral medications that block glucose reabsorption in the kidneys, lowering blood sugar and blood pressure. Clinical trials have demonstrated benefits in type 2 diabetes, heart failure, and chronic kidney disease, making them one of the most widely prescribed drug classes today. Common side effects worth monitoring include urinary tract symptoms, genital infections, fatigue, and orthostatic hypotension — all of which SGLT2 Diary helps you track. MEDICAL DISCLAIMER SGLT2 Diary is an informational tracking tool only. It does not provide medical advice, diagnosis, or treatment recommendations. Always consult your healthcare provider before making any changes to your medication or treatment plan.